Le Lézard
Classified in: Health, Business
Subjects: TNM, VEN

Health & Wellness Platform Anchored by Vanterra Capital Acquired by Clorox


NEW YORK, March 20, 2018 /PRNewswire/ -- Less than 24 months after completing its anchor investment in WM Partners' ("WM") debut fund, Vanterra Capital, LLC ("Vanterra") alongside WM has agreed to sell the platform to the Clorox Company (NYSE: CLX) for $700 million, representing approximately 3.5 times calendar year 2017 sales.  Additional terms of the transaction were not disclosed.

 (PRNewsfoto/Vanterra Capital)

In 2016, Vanterra completed an anchor investment in WM's HPH Specialized Fund I, a single-asset vehicle focused on acquiring lower-middle market brands in the Vitamins, Minerals and Supplements ("VMS") and Natural Personal Care sectors and integrating them into Nutranext LLC (FKA "Wellnext LLC"), a vertically-integrated developer, manufacturer, and marketer of dietary and nutritional supplements.  

Under WM Partners' direction, Nutranext nearly doubled its revenues and more than quadrupled its EBITDA. This growth was driven by a combination of operational organic growth and four strategic add-on acquisitions of leading nutritional supplements brands in fast-growing categories in the retail and DTC channels that complemented Nutranext's existing portfolio. The vision with Nutranext was to create a scalable platform that would be attractive to a potential buyer by consolidating the highly fragmented U.S. supplements market by acquiring and integrating leading brands. With these acquisitions, Nutranext expanded its national footprint with offices across the U.S., diversified its product mix into other leading categories such as collagen, anti-stress and sleep products, optimized its distribution capabilities across all channels, and strengthened the team.

Vanterra's strategic investment into WM Partners and Nutranext resulted from the Firm's growing activity in the health & wellness sector and multi-year industry deep dive. The supplements subsector alone is a $41 billion industry1.

In addition to Nutranext, Vanterra has made direct investments into multiple other health & wellness and consumer lifestyle companies. Vanterra benefits from a flexible investment approach and has established a number of other specialized fund platforms in partnership with management teams in sectors such as healthcare services, energy & materials, secondaries, credit, and special situations. 

About Vanterra Capital

Vanterra Capital is a global private equity firm that manages assets for a diverse investor base of ultra-high net worth partners and leading institutions. Vanterra seeks to establish strategic relationships with specialized managers or operators that have a unique competitive advantage within specific industries or strategies.  By partnering with specialized management teams to create premier investment platforms, Vanterra seeks to opportunistically deploy capital to support the strategic and financial objectives of rapidly growing companies. For more information visit: www.vanterra.com.

About Nutranext

Headquartered in Sunrise, Florida, the Nutranext family of brands delivers research-backed nutritional supplements for every consumer life stage. Anchor brands within the Nutranext portfolio include a GMP-certified manufacturer with 30 years of leadership in supplement manufacturing, Rainbow Light®, Champion Performance®, Natural Vitality®, and NeoCell® among many other leading brands. Guided by three generations of family heritage, Nutranext is committed to the highest standards of corporate social responsibility, including product quality and purity testing, sustainability practices, and corporate giving programs, to help foster a vibrant state of health in families everywhere. For more information, visit: www.nutranext.net.


1 Nutrition Business Journal.

 

SOURCE Vanterra Capital


These press releases may also interest you

at 08:10
bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced David Elzi, Ph.D., has been named Vice President of...

at 08:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the availability of Over the Counter ("OTC") Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application ("ANDA") approval from the...

at 08:10
BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic...

at 08:10
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company's Deltacel-01 Phase 1 clinical trial....

at 08:05
The Board of Directors of McKesson Corporation yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on July 1, 2024, to stockholders of record on June 3, 2024. About McKesson Corporation...

at 08:05
symplr®, a leading provider of enterprise healthcare operations software, today announced a new partnership integrating award-winning healthcare worker payments technology from Branch, a workforce payments platform. With the integrated pay solution,...



News published on and distributed by: